While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.Sales from two of Vertex Pharmaceuticals’ newest products appear to have dampened an earnings report that otherwise met or slightly exceeded expectations on Wall Street.Vertex recorded a […]
